EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy

Yihao Huang, Guihong Lin, Sinong Liu, Mingying Chen, Chaoyong Yang, Yanling Song iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202400599 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemBioChem, 2025. Verfasst von Yihao Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, The Key Laboratory of Chemical Biology of Fujian Province, State Key Laborato…. Hauptthemen laut MEDLINE: Immunotherapy, Aptamers, Nucleotide, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Ministry of Science and Technology of China, National Natural Science Foundation of China, Scientific Research Foundation of Xiang An Biomedicine Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer has long been a significant threat to human life and health. The advent of immune checkpoint blockade strategies has reversed cancer‐induced immune suppression, advanced the development of immunotherapy, and offered new hope in the fight against cancer. Aptamers, which possess the same specificity and affinity as antibodies, are advantageous due to their synthetic accessibility and ease of modification, providing novel insights for immune checkpoint research. In this review, we outline the key aptamers currently developed for immune checkpoints such as CTLA‐4, PD‐1, PD−L1 and Siglec‐15. We explore their potential in therapeutic strategies, including functionalizing or engineering aptamers for covalent binding, valency control, and nanostructure assembly, as well as investigating molecular mechanisms such as glycosylated protein functions and cell‐cell interactions. Finally, the future applications of aptamers in immunotherapy are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyAptamers, NucleotideNeoplasmsImmune Checkpoint InhibitorsHumansB7-H1 AntigenProgrammed Cell Death 1 ReceptorAnimals

Stichwörter der Autor:innen

AptamerCancer immunotherapyImmune Checkpoint

Substanzen

Aptamers, NucleotideImmune Checkpoint InhibitorsB7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, human

Autor:innen und Institutionen

  • The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, The Key Laboratory of Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, Department of Chemical Bio…
  • Renji Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

ORCID-Profile: Yanling Song

Förderung

  • Ministry of Science and Technology of China
  • National Natural Science Foundation of China
  • Scientific Research Foundation of Xiang An Biomedicine Laboratory
  • Program for Changjiang Scholars
  • Innovative Research Team in University

Zitieren

APA

Huang, Y., Lin, G., Liu, S., Chen, M., Yang, C., & Song, Y. (2025). Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy. ChemBioChem. https://doi.org/10.1002/cbic.202400599

Vancouver

Huang Y, Lin G, Liu S, Chen M, Yang C, Song Y. Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy. ChemBioChem. 2025. doi:10.1002/cbic.202400599

BibTeX
@article{Huang2025,
  author = {Huang, Yihao and Lin, Guihong and Liu, Sinong and Chen, Mingying and Yang, Chaoyong and Song, Yanling},
  title = {Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202400599}
}
Kostenlos starten →